News >

Isatuximab Triplet Highly Active in Relapsed/Refractory Myeloma

Caroline Seymour
Published: Wednesday, Jul 24, 2019

Paul G. Richardson, MD, clinical program leader, director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician at Dana-Farber Cancer Institute

Paul G. Richardson, MD

Data from the phase III ICARIA-MM trial showed that the CD38-directed monoclonal antibody isatuximab should be used earlier in multiple myeloma treatment rather than reserving it for later use as salvage therapy, explained Paul G. Richardson, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication